Overview
- Biogen and private biotech RayThera have signed a definitive agreement under which Biogen will acquire RayThera for an upfront payment plus clinical and regulatory milestone payments that could total as much as $1 billion.
- RayThera’s lead anti-inflammatory candidate is slated to enter Phase 1 development in early Q3 2026 and, if the deal closes, Biogen will take responsibility for further development, manufacturing and global commercialization.
- The transaction is expected to close in Q3 2026 subject to customary closing conditions and regulatory approvals, meaning the timing of integration and payments depends on those approvals and clinical progress.
- RayThera recently completed a Series A financing co-led by Foresite Capital and OrbiMed Advisors with participation from TTM Capital, leaving the company with early-stage assets backed by experienced life‑science investors.
- The deal deepens Biogen’s push into immunology and new disease areas while limiting near-term cash exposure through milestone-heavy payments, so investors and patients will watch the upcoming Phase 1 start and regulatory clearances as key signals of value realization.